Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Vaxxa AB is a Swedish company that operates a digital auction platform for buying and selling used vehicles, machinery, construction equipment, and other industrial goods. Through its online marketplace, Vaxxa AB serves both private individuals and businesses, offering a structured way to handle second-hand assets in sectors where efficient resale and reuse are important. The platform combines auction services with self-service tools, helping sellers list items and buyers access a broad selection of used products in one place. Vaxxa AB plays a role in the circular economy by supporting the trading of pre-owned assets across automotive, industrial, and construction-related markets. Based in Sweden, the company focuses on making asset transactions more accessible and transparent for participants in these segments.
kr 0.03
+kr 0.00 (+0.65%)
EOD Jun 26, 2026 · Twelve Data
The business is unprofitable at the operating level (-12.50% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 8.1% YoY. Margins deteriorated 12.9pp alongside, both lines moving the wrong way.
ROIC dropped from 1.96% to -41.85%, capital efficiency is deteriorating. Operating margin contracted 12.9pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 81M
▼ -8.1% YoY
Net Income (TTM)
-kr 10M
▼ -2510.8% YoY
Op. Margin
-12.85%
▼ -12.9pp YoY
ROIC
-41.85%
▼ -43.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 3M
▲ +170.4% YoY
Op. Cash Flow (TTM)
kr 3M
▲ +174.7% YoY
Net Debt
-kr 7M
Net Cash Position
Cash & Equiv.
kr 8M
Continue Research
Vaxxa AB (VAXXA.XSTO) trades below a two-stage DCF intrinsic value of about SEK 2.59 per share, so at SEK 0.03 the stock looks undervalued (8,193.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Vaxxa AB scores 34/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 2.59 per share for VAXXA.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 1.94. At today's SEK 0.03, that puts the stock about 8,193.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Vaxxa AB scores 34 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -12.9% operating margin and a -41.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. VAXXA.XSTO currently trades below its estimated intrinsic value and scores 34/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.